Consun Pharmaceutical Group Limited (HKG:1681)
Hong Kong · Delayed Price · Currency is HKD 13.69
-0.01 (-0.07%)
Jul 31, 2026, 4:08 PM HKT
HKG:1681 Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11,493 | 13,139 | 6,771 | 3,780 | 3,193 | 3,495 | |
Market Cap Growth | 4.25% | 94.05% | 79.14% | 18.38% | -8.64% | 43.27% |
Enterprise Value | 7,723 | 9,318 | 3,788 | 1,258 | 1,225 | 2,132 |
Last Close Price | 13.69 | 15.21 | 7.55 | 3.80 | 2.95 | 3.04 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 9.76 | 10.95 | 6.99 | 4.37 | 4.14 | 4.82 |
Forward PE | 8.01 | 9.81 | 6.57 | 4.09 | 4.18 | 3.80 |
PS Ratio | 3.02 | 3.46 | 2.14 | 1.33 | 1.21 | 1.39 |
PB Ratio | 2.13 | 2.44 | 1.45 | 0.88 | 0.82 | 0.98 |
P/TBV Ratio | 2.42 | 2.77 | 1.66 | 1.03 | 1.00 | 1.25 |
P/FCF Ratio | 9.03 | 10.33 | 6.51 | 4.48 | 3.15 | 4.54 |
P/OCF Ratio | 8.52 | 9.74 | 5.85 | 4.19 | 2.98 | 3.92 |
PEG Ratio | - | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.03 | 2.45 | 1.20 | 0.44 | 0.46 | 0.85 |
EV/EBITDA Ratio | 5.70 | 6.93 | 3.45 | 1.27 | 1.38 | 2.38 |
EV/EBIT Ratio | 6.03 | 7.27 | 3.65 | 1.38 | 1.51 | 2.63 |
EV/FCF Ratio | 6.07 | 7.32 | 3.64 | 1.49 | 1.21 | 2.77 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.04 | 0.04 | 0.06 | 0.13 | 0.13 | 0.21 |
Debt / EBITDA Ratio | 0.17 | 0.17 | 0.26 | 0.57 | 0.58 | 0.83 |
Debt / FCF Ratio | 0.19 | 0.19 | 0.27 | 0.67 | 0.51 | 0.97 |
Net Debt / Equity Ratio | -0.76 | -0.76 | -0.82 | -0.78 | -0.75 | -0.62 |
Net Debt / EBITDA Ratio | -3.06 | -3.06 | -3.49 | -3.42 | -3.28 | -2.49 |
Net Debt / FCF Ratio | -3.23 | -3.23 | -3.68 | -4.01 | -2.88 | -2.89 |
Asset Turnover | 0.56 | 0.56 | 0.52 | 0.50 | 0.51 | 0.49 |
Inventory Turnover | 2.42 | 2.42 | 2.07 | 1.99 | 2.12 | 2.13 |
Quick Ratio | 2.98 | 2.98 | 3.09 | 2.60 | 2.47 | 2.06 |
Current Ratio | 3.22 | 3.22 | 3.32 | 2.86 | 2.68 | 2.25 |
Return on Equity (ROE) | 23.60% | 23.60% | 22.07% | 21.38% | 21.53% | 21.64% |
Return on Assets (ROA) | 11.74% | 11.74% | 10.73% | 9.93% | 9.66% | 9.93% |
Return on Invested Capital (ROIC) | 91.41% | 108.02% | 106.82% | 88.13% | 67.03% | 50.16% |
Return on Capital Employed (ROCE) | 23.10% | 23.10% | 21.80% | 20.60% | 20.20% | 22.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 10.44% | 9.13% | 14.31% | 22.87% | 24.18% | 20.73% |
FCF Yield | 11.07% | 9.68% | 15.37% | 22.34% | 31.73% | 22.03% |
Dividend Yield | 5.84% | 4.80% | 7.94% | 11.85% | 10.18% | 9.86% |
Payout Ratio | 46.23% | 46.23% | 74.75% | 41.59% | 18.67% | 33.56% |
Buyback Yield / Dilution | -2.77% | -2.77% | -4.12% | -0.91% | 1.58% | 1.54% |
Total Shareholder Return | 3.08% | 2.03% | 3.82% | 10.95% | 11.76% | 11.39% |